
Global Anti-Obesity Prescription Market Growth 2025-2031
Description
The global Anti-Obesity Prescription market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Obesity is a public health problem. Obesity is a genetic and chronic metabolic disease involving accumulation of excessive or abnormal fat in the body. It contributes to risk of chronic conditions such as cancer, hypertension, cardiovascular diseases, diabetics, obstructive sleep apnea, ventilatory failure, renal failure and asthma. According to a World Health Organization (WHO) report published in 2014, around 3.4 million adults in the world die each year due to obesity related issues. Increasing prevalence of obesity among children and adults is posing a threat and developing nations. Effective intervention strategies such as increased physical activity, behavioral and dietary changes are commonly used to control and prevent obesity. Obesity has a major impact on population longevity and health related expense.
According to our Wellness & Health Research Center, the global wellness & health economy was valued at US dollars 4.8 trillion. Asia Pacific was the region with the highest spending on big health in 2022, with a total spending of $1.68 trillion, followed by North America ($1.42 trillion) and Europe ($1.0 trillion). According to the health industry accounting analysis data disclosed by the Health Development Research Center of the National Health Commission, from 2019 to 2021, the market size of the health service industry grew by an average of 7.0% per year, and the specific data increased from 7.7 trillion yuan to 8.8 trillion yuan. China"s health industry revenue reached 8.0 trillion yuan in 2021, with an increase of 8.1%. According to public information, in 2022, there were about 1.2 billion obesity cases worldwide, among them, the number of obesity cases in China reached 230 million. Wellness & Health Research Center, the global sports economy was valued at 750 billion in 2022, 92% of global spending on physical activity occurs in Asia Pacific, North America and Europe. And China and the United States accounted for 44% of total sports spending.
LP Information, Inc. (LPI) ' newest research report, the “Anti-Obesity Prescription Industry Forecast” looks at past sales and reviews total world Anti-Obesity Prescription sales in 2024, providing a comprehensive analysis by region and market sector of projected Anti-Obesity Prescription sales for 2025 through 2031. With Anti-Obesity Prescription sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-Obesity Prescription industry.
This Insight Report provides a comprehensive analysis of the global Anti-Obesity Prescription landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-Obesity Prescription portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anti-Obesity Prescription market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-Obesity Prescription and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-Obesity Prescription.
This report presents a comprehensive overview, market shares, and growth opportunities of Anti-Obesity Prescription market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Bupropion and Naltrexone
Orlistat
Lorcaserin
Phentermine and Topiramate
Liraglutide
Segmentation by Application:
Hospital Pharmacies
Retail Pharmacies
E-Commerce
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Zydus Cadila
Akrimax Pharmaceuticals
Zealand Pharma
Arrowhead Research
Arena Pharmaceuticals
Compellis Pharmaceuticals
Yungjin Pharm
Alpex Pharma
Bridge BioResearch
Key Questions Addressed in this Report
What is the 10-year outlook for the global Anti-Obesity Prescription market?
What factors are driving Anti-Obesity Prescription market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Anti-Obesity Prescription market opportunities vary by end market size?
How does Anti-Obesity Prescription break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Obesity is a public health problem. Obesity is a genetic and chronic metabolic disease involving accumulation of excessive or abnormal fat in the body. It contributes to risk of chronic conditions such as cancer, hypertension, cardiovascular diseases, diabetics, obstructive sleep apnea, ventilatory failure, renal failure and asthma. According to a World Health Organization (WHO) report published in 2014, around 3.4 million adults in the world die each year due to obesity related issues. Increasing prevalence of obesity among children and adults is posing a threat and developing nations. Effective intervention strategies such as increased physical activity, behavioral and dietary changes are commonly used to control and prevent obesity. Obesity has a major impact on population longevity and health related expense.
According to our Wellness & Health Research Center, the global wellness & health economy was valued at US dollars 4.8 trillion. Asia Pacific was the region with the highest spending on big health in 2022, with a total spending of $1.68 trillion, followed by North America ($1.42 trillion) and Europe ($1.0 trillion). According to the health industry accounting analysis data disclosed by the Health Development Research Center of the National Health Commission, from 2019 to 2021, the market size of the health service industry grew by an average of 7.0% per year, and the specific data increased from 7.7 trillion yuan to 8.8 trillion yuan. China"s health industry revenue reached 8.0 trillion yuan in 2021, with an increase of 8.1%. According to public information, in 2022, there were about 1.2 billion obesity cases worldwide, among them, the number of obesity cases in China reached 230 million. Wellness & Health Research Center, the global sports economy was valued at 750 billion in 2022, 92% of global spending on physical activity occurs in Asia Pacific, North America and Europe. And China and the United States accounted for 44% of total sports spending.
LP Information, Inc. (LPI) ' newest research report, the “Anti-Obesity Prescription Industry Forecast” looks at past sales and reviews total world Anti-Obesity Prescription sales in 2024, providing a comprehensive analysis by region and market sector of projected Anti-Obesity Prescription sales for 2025 through 2031. With Anti-Obesity Prescription sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-Obesity Prescription industry.
This Insight Report provides a comprehensive analysis of the global Anti-Obesity Prescription landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-Obesity Prescription portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anti-Obesity Prescription market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-Obesity Prescription and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-Obesity Prescription.
This report presents a comprehensive overview, market shares, and growth opportunities of Anti-Obesity Prescription market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Bupropion and Naltrexone
Orlistat
Lorcaserin
Phentermine and Topiramate
Liraglutide
Segmentation by Application:
Hospital Pharmacies
Retail Pharmacies
E-Commerce
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Zydus Cadila
Akrimax Pharmaceuticals
Zealand Pharma
Arrowhead Research
Arena Pharmaceuticals
Compellis Pharmaceuticals
Yungjin Pharm
Alpex Pharma
Bridge BioResearch
Key Questions Addressed in this Report
What is the 10-year outlook for the global Anti-Obesity Prescription market?
What factors are driving Anti-Obesity Prescription market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Anti-Obesity Prescription market opportunities vary by end market size?
How does Anti-Obesity Prescription break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
95 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Anti-Obesity Prescription by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Anti-Obesity Prescription by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.